Intelligence Profile
Safety Profile
Evidence Limitation: The safety data for the combination of Ipamorelin + CJC-1295 + IGF-1 LR3 is extremely limited. No controlled clinical trials were found specifically evaluating this three-compound combination, and safety information is largely based on individual compound data and case reports.
Known Side Effects
Individual compound effects that may apply:
Ipamorelin:
- Generally considered well-tolerated in limited studies
- Potential injection site reactions
- Possible water retention
- Headache and fatigue reported anecdotally
CJC-1295:
- Injection site reactions (redness, swelling)
- Flushing
- Potential sleep disturbances
- Water retention
IGF-1 LR3:
- Hypoglycemia (potentially serious)
- Joint pain
- Muscle pain
- Potential organ enlargement with prolonged use
- Injection site reactions
Combination risks: The safety profile of using these compounds together is unknown and may involve additive or synergistic effects.
Contraindications
Established contraindications include:
- Active cancer or history of cancer (due to growth-promoting effects)
- Diabetic retinopathy
- Severe illness or critical medical conditions
- Pregnancy and breastfeeding
- Pediatric use (unless under strict medical supervision)
Drug Interactions
Potential interactions:
- Insulin and diabetes medications (increased hypoglycemia risk with IGF-1 LR3)
- Corticosteroids (may alter growth hormone effects)
- Thyroid medications (potential interaction with growth hormone axis)
Evidence gap: Specific drug interaction data for this combination is not available in clinical literature.
High-Risk Populations
Should avoid or use with extreme caution:
- Individuals with diabetes or glucose metabolism disorders
- Those with cardiovascular disease
- Patients with kidney or liver disease
- Anyone with current or past malignancies
- Individuals under 25 years (due to potential interference with natural growth processes)
Critical Safety Considerations
The 2026 review in Frontiers in Endocrinology highlights significant concerns about patient self-administration of growth hormone-modulating peptides, noting a substantial gap between clinical evidence and real-world use.
Important: This combination lacks comprehensive safety data from controlled studies. Long-term effects, optimal dosing, and safety in various populations remain unknown.
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical consultation. Anyone considering these compounds should work closely with a qualified healthcare provider familiar with peptide therapies.